A clinical stage company developing a novel small molecule for the treatment of Alzheimer’s Disease.

Recognify Life Sciences is a clinical stage pharmaceutical company and now a subsidiary of ATAI Life Sciences. Its lead small molecule asset, FSV7-007, was exclusively licensed from Allergan and is now being developed by Recognify for the treatment of neurodegenerative and neurocognitive diseases. In the US, approximately 10% of the population over the age of 65 suffers from Alzheimer’s disease (AD) and AD-related dementia. Despite this high prevalence, there have been few advances in therapeutic agents to treat AD. FSV7-007 has an orthogonal mechanism of action relative to existing AD therapeutics, so the company is initially pursuing FDA approval for the treatment of early to moderate AD with the potential to expand into other neurocognitive indications such as anxiety.